Vical attracts BMS with Vaxfectin adjuvant, pDNA drug discovery tech
This article was originally published in Scrip
Executive Summary
Vical has signed an agreement with the first licensee for Vaxfectin, granting Bristol-Myers Squibb non-exclusive worldwide rights to the San Diego, US-based company's DNA vaccine adjuvant and also DNA immunisation technology for use in the discovery and production of therapeutic antibodies.